[The value of metformin in therapy of type 2 diabetes: effect on insulin resistance, diabetic control and cardiovascular risk factors].
In this review article recently published controlled clinical studies of metformin treatment in type-2 diabetic patients are summarized. Several studies demonstrate that body weight decreases and insulin resistance improves--as evaluated by peripheral glucose utilisation--under metformin treatment. HbA1c is lowered by approximately 20% (absolute decrease of HbA1c: 1.0%-1.5%). Since plasma lipid values and plasminogen-activator-inhibitor (PAI-1) concentrations are also lowered under metformin therapy, it currently represents the treatment of choice for the obese group of type-2 diabetic patients.
Schernthaner
G
G
Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien.
D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D008055:Lipids / Q000097:blood; D008687:Metformin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D012307:Risk Factors
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D008055:Lipids; D008687:Metformin; D017395:Plasminogen Activator Inhibitor 1
Die Bedeutung von Metformin in der Therapie des Typ-2-Diabetes: Effekt auf Insulinresistenz, Diabeteseinstellung und kardiovaskuläre Risikofaktoren.